{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"16"}],"units":"Participants"}],"groups":[{"description":"Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"BG000","title":"AZD8853 300 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"BG001","title":"AZD8853 1000 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"BG002","title":"AZD8853 3000 mg"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.2","value":"62.0"},{"groupId":"BG001","spread":"4.2","value":"62.8"},{"groupId":"BG002","spread":"7.4","value":"65.1"},{"groupId":"BG003","spread":"7.3","value":"63.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"comment":"Data are not reported due to concerns with participant's confidentiality.","groupId":"BG000","value":"NA"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG003","value":"NA"}],"title":"Female"},{"measurements":[{"comment":"Data are not reported due to concerns with participant's confidentiality.","groupId":"BG000","value":"NA"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"},{"comment":"Total not calculated because data are not available (NA) in one or more arms.","groupId":"BG003","value":"NA"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"13"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}],"title":"Not reported"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Safety set included all participants who received any amount of investigational product (IP)."}